AE 37

Drug Profile

AE 37

Alternative Names: AE37; AE37 peptide/GM-CSF HER2 peptide vaccine; AE37 vaccine; Cancer vaccine AE37 - Antigen Express; Cancer vaccine AE37 - Generex-Biotechnology; Cancer vaccine HER2/neu Antigen Express AE37; Cancer vaccine HER2/neu Generex Biotechnology AE37; Her-2/neu Breast cancer; Her-2/neu Prostate cancer; Ii-key hybrid cancer vaccine AE37; Ii-key hybrid HER2/neu vaccine Antigen Express AE37; Ii-key hybrid HER2/neu vaccine Generex Biotechnology AE37; Ii-Key/Her-2/neu(776-790) vaccine; Modified HER2/neu peptide AE37 vaccine

Latest Information Update: 09 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigen Express
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Regulatory T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Prostate cancer
  • Discontinued Ovarian cancer

Most Recent Events

  • 05 Oct 2018 Generex, in conjunction with Merck and NSABP Foundation intends to file an IND application for a phase II trial in triple negative Breast cancer (Metastatic disease, Combination therapy) in October 2018
  • 05 Oct 2018 Generex, Merck and NSABP Foundation plan a phase II trial of AE 37 for triple negative Breast cancer (Metastatic disease, Combination therapy) in the first quarter of 2019
  • 05 Oct 2018 Shenzhen Bioscien plans a phase II trial in Prostate cancer in Europe in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top